# US 2019/0167791 A1 · Immunotherapeutic uses of ex vivo generated foxp3+ regulatory t cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167791 A1
- Document ID: US20190167791A1
- Status: Published application
- Kind: A1
- Application number: 16/322,188
- Filed: 2017-08-04
- Published: 2019-06-06
- Earliest claimed: 2016-08-05
- Assignees: Inserm (Institut National De La Sante Et De La Recherche Medicale); Medecine Et Innovation; Universite Paris Diderot—Paris 7; Centre National de la Recherche Scientifique (CNRS)
- Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale); Medecine et Innovation; Universite Paris Diderot - Paris 7; Centre National de la Recherche Scientifique (CNRS
- Inventors: Daniel ZAGURY; Helene LE BUANEC; Sophie DUCHEZ; Valerie SCHIAVON; Armand BENSUSSAN
- Web page: https://patentgrep.com/patent/US20190167791A1

## CPC

- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 39/001: {Preparations to induce tolerance to non-self, e.g. prior to transplantation}
- A61K 39/39525: {Purification}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/19: Dendritic cells
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/32: T-cell receptors [TCR]
- A61K 40/34: Antigenic peptides
- A61K 40/42: Cancer antigens
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C12N 5/0637: {Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg}
- C12N 2501/02: Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
- C12N 2501/15: Transforming growth factor beta (TGF-β)
- C12N 2501/2302: Interleukin-2 (IL-2)
- C12N 2501/2315: Interleukin-15 (IL-15)
- C12N 2501/999: Small molecules not provided for elsewhere
- C12N 2502/095: mammary cells
- C12N 2502/1121: Dendritic cells
- C12N 2502/30: tumour cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to therapeutic uses of ex vivo generated Foxp3+ regulatory T cells. The inventors showed the presence of Foxp3+ expressing T cells in tumor infiltrating lymphocytes (TILs) isolated from luminal-B breast cancer. The inventors performed an ex vivo generation and expansion of specific CD3+ TCRy8+ expressing Foxp3: CD3+ TCRy8+ T cells maintain their Foxp3 level and their suppressive activity, after a further 21-day-culture. They also showed that tumor Ag-specific CD3+ TCR Va24+ T cells maintain their ability to perform suppressive function in pro-inflammatory conditions. In particular, the present invention relates to immunotherapeutic uses of at least one of ex vivo generated Foxp3+regulatory T cells population selected among a MHCII restricted CD4+Foxp3+regulatory T cells population, a y8 Foxp3+regulatory T cells population and an invariant Foxp3+regulatory T cells population.

## Claims

### Claim 1

An immunogenic product, a pharmaceutical composition or a vaccine composition comprising at least one inactivated ex vivo generated Foxp3+ regulatory T cell population selected from the group consisting of a MHCII restricted CD4+ Foxp3+ regulatory T cell population, a γδ Foxp3+ regulatory T cell population and an invariant Foxp3+ regulatory T cell population.

### Claim 2 (depends on 1)

The pharmaceutical composition comprising of claim 1, further comprising at least one pharmaceutically acceptable excipient.

### Claim 3 (depends on 1)

The vaccine composition of claim 1, further comprising at least one adjuvant.

### Claim 4 (depends on 2)

The pharmaceutical composition of claim 2, wherein said at least one ex vivo generated regulatory T cells population remains stable when placed in inflammatory condition.

### Claim 5 (depends on 1)

A method of treating cancer in a subject in need thereof, comprising
administering to the subject a therapeutically effective amount of an immunogenic product, pharmaceutical composition or vaccine composition according to claim 1.

### Claim 6 (depends on 1)

A method for preparing the immunogenic product, pharmaceutical composition or vaccine composition according to claim 1, comprising:
identifying from a tumor sample obtained from a subject at least one overrepresented regulatory T cell population selected from the group consisting of a MHCII restricted CD4+ Foxp3+ regulatory T cell population, a γδ Foxp3+ regulatory T Bells cell population and an invariant Foxp3+ regulatory T cell population,
ex vivo generating the at least one overrepresented regulatory T cell population, and
inactivating the at least one ex vivo generated regulatory T cell population.

### Claim 7 (depends on 4)

A method of performing cell therapy in a subject in need thereof comprising
administering to the subject a therapeutically effective amount of a pharmaceutical composition according to claim 4.

### Claim 8 (depends on 4)

A method of treating inflammatory or autoimmune diseases or for preventing transplant rejection or graft versus host disease (GVHD) in a subject in need thereof, comprising
administering to the subject a therapeutically effective amount of a pharmaceutical composition according to claim 4.

### Claim 9 (depends on 1)

The immunogenic product, pharmaceutical composition or vaccine composition according to claim 1, wherein the at least one inactivated ex vivo generated regulatory T cell population is obtained or expanded by a method comprising:
for the MHCII restricted CD4+ Foxp3+ regulatory T cell population: culturing CD3+ CD4+ CD25+ T cells in the presence of a TCRαβ cell activator and the following agents: i) a cAMP (Cyclic adenosine monophosphate) activator, ii) a TGFβ (Transforming growth factor beta) pathway activator, iii) a mTOR inhibitor, and optionally iv) at least one cytokine selected in from the group consisting of IL-2, IL-7, IL-15 and TSLP, for at least 5 days;
for the γδ Foxp3+ regulatory T cell population: culturing CD3+ TCRγδ+ T cells in the presence of a γδ T cell activator and the following agents: i) a cAMP (Cyclic adenosine monophosphate) activator, ii) a TGFβ (Transforming growth factor beta) pathway activator, iii) a mTOR inhibitor, and optionally iv) at least one cytokine selected from the group consisting of IL-2, IL-7, IL-15 and TSLP, for at least 5 days;
for the invariant Foxp3+ regulatory T cell population: culturing CD3+ Vα24+ T cells in the presence of an invariant T cell activator and the following agents: i) a cAMP (Cyclic adenosine monophosphate) activator, ii) a TGFβ (Transforming growth factor beta) pathway activator, iii) a mTOR inhibitor, and optionally iv) at least one cytokine selected from the group consisting of IL-2, IL-7, IL-15 and TSLP, for at least 5 days.

### Claim 10 (depends on 9)

The immunogenic product, pharmaceutical composition or vaccine composition according to claim 9, wherein the TCRαβ cell activator is a polyclonal TCRαβ cell activator; the γδ T cell activator is a polyclonal γδ T cell activator; and the invariant T cell activator is a polyclonal invariant T cell activator.

### Claim 11 (depends on 9)

The immunogenic product, pharmaceutical composition or vaccine composition according to claim 9, wherein the TCRαβ cell activator is an antigen-specific TCRαβ cell activator; the γδ T cell activator is an antigen-specific γδ T cell activator, and the invariant T cell activator is an antigen-specific invariant T cell activator.

### Claim 12 (depends on 9)

The immunogenic product, pharmaceutical composition or vaccine composition according to claim 9, wherein the cAMP activator is prostaglandin E2 (PGE2), an EP2 or EP4 agonist, a membrane adenine cyclase activator or a metabotropic glutamate receptor agonist.

### Claim 13 (depends on 9)

The immunogenic product, pharmaceutical composition or vaccine composition according to claim 9, wherein the TGFβ pathway activator is TGFβ, bone morphogenetic proteins (BMPs), growth and differentiation factors (GDFs), anti-mullerian hormone (AMH), activin or nodal.

### Claim 14 (depends on 9)

The immunogenic product, pharmaceutical composition or vaccine composition according to claim 9, wherein the mTOR inhibitor is rapamycin, a rapamycin analog, wortmannin; theophylline; caffeine; epigallocatechin gallate (EGCG), curcumin, resveratrol; genistein, 3, 3-diindolylmethane (DIM), LY294002 (2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one), PP242, PP30, Torin1, Ku-0063794, WAY-600, WYE-687, WYE-354, GNE477, NVP-BEZ235, PI-103, XL765 or WJDO08.

### Claim 15

(canceled)

### Claim 16 (depends on 10)

The immunogenic product, pharmaceutical composition or vaccine composition according to claim 10, wherein the polyclonal TCRαP cell activator is an anti-CD3 antibody or an anti-TCRαβ antibody.

### Claim 17 (depends on 10)

The immunogenic product, pharmaceutical composition or vaccine composition according to claim 10, wherein the polyclonal γδ T cell activator is an anti-TCR γδ antibody or a non peptide phosphoantigen.

### Claim 18 (depends on 10)

The immunogenic product, pharmaceutical composition or vaccine composition according to claim 10, wherein the polyclonal invariant T cell activator is a Vα24 activator.

### Claim 19 (depends on 11)

The immunogenic product, pharmaceutical composition or vaccine composition according to claim 11, wherein the antigen-specific TCRαβ cell activator is tolerogenic dendritic cells (DCs) pulsed with at least one self-peptide antigen.

### Claim 20 (depends on 11)

The immunogenic product, pharmaceutical composition or vaccine composition according to claim 11, wherein the antigen-specific γδ T cell activator is tolerogenic dendritic cells (DCs) pulsed with at least one bisphosphonate.

### Claim 21 (depends on 20)

The immunogenic product, pharmaceutical composition or vaccine composition according to claim 20, wherein the at least one bisphosphonate is at least one aminobisphosphonate.

### Claim 22 (depends on 11)

The immunogenic product, pharmaceutical composition or vaccine composition according to claim 11, wherein the antigen-specific invariant T cell activator is tolerogenic dendritic cells (DCs) expressing CD1 and pulsed with at least one non peptide lipid antigen.
